Revolutionary GI diagnostics and therapeutics are on the horizon
Our ingestible technologies show promising results that could transform clinical diagnostics and therapeutics for GI disease.
Current methods for sampling the gut make it difficult for healthcare providers to accurately diagnose and monitor gastrointestinal diseases. Even after diagnosis, drug therapy presents a number of challenges, including achieving the most effective therapeutic dose at the site of disease.
Two meta-analyses presented by Biora at the 2019 American College of Gastroenterology (ACG) meeting show significant limitations to current diagnostics for small intestine bacterial overgrowth (SIBO) and support the need for novel tools.
- Lee NS, et al. Characterization of the bacterial makeup and quantitative distribution in patients with suspected SIBO: A meta-analysis. Poster presented at ACG, 2019. San Antonio, Texas.
- Stylli J, et al. Accuracy of glucose breath testing for SIBO using endoscopy aspirate cultures as a reference standard: A meta-analysis. Poster presented at ACG, 2019. San Antonio, Texas.